翰宇药业调整核心管理团队 原总裁退休离任，聘任双执行总裁“补位”

Core Viewpoint - Han Yu Pharmaceutical has undergone significant management changes, appointing two new executive presidents to adapt to a complex market environment and pursue internationalization strategies [2][3][4]. Management Changes - The resignation of PINXIANG YU, the former executive president, was due to retirement, and he will not hold any positions in the company or its subsidiaries post-resignation [3]. - The board has appointed Tang Yangming and Shen Yaping as new executive presidents, with their terms lasting until the current board's term ends [3][4]. - Tang Yangming has over 20 years of experience in peptide drug research and has been with Han Yu Pharmaceutical since 2005 [3]. - Shen Yaping, an external hire, has a notable background in international business from his tenure at Jiangsu Hengrui Medicine Co., Ltd., where he held various senior roles [4]. Recent Personnel Adjustments - Han Yu Pharmaceutical has made multiple personnel adjustments in the second half of the year, affecting key positions such as vice presidents, board secretaries, and committee members [5][6]. - The company has seen a rapid succession of management changes, including the resignation of vice president Zhang Baole and board secretary Yang Di, both of whom left for personal reasons [6]. Financial Performance - In the first three quarters of the year, Han Yu Pharmaceutical reported a revenue of 683 million yuan, marking an 82.06% year-on-year increase, and a net profit of 71.35 million yuan, indicating a turnaround from losses [7]. - The company achieved an operating cash flow of 271 million yuan, a significant increase of 207.37%, setting a historical high for the same period [7].